title: Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction.
abstract: A strident debate has been surging in the interventional cardiology community over the triumvirate of efficacy, safety, and cost of bivalirudin compared with heparin for anticoagulation of patients with ST-segment elevation myocardial infarction.
authors: Walter
authors: W
authors: Alexander